Evidence map›Paper›PMID 30526664›Full record

ArticleReproductive health2018

The ReceptIVFity cohort study protocol to validate the urogenital microbiome as predictor for IVF or IVF/ICSI outcome.

Rivka Koedooder, Martin Singer, Sam Schoenmakers, Paul Hendrik Maria Savelkoul, Servaas Antonie Morré, Jonathan Dennis de Jonge, Linda Poort, Willem-Jan Simon Stephanus Cuypers, Andries Edward Budding, Joop Stephanus Elisabeth Laven and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Reproductive health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05328999 (Fertility and the Microbiome), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05328999 recruitingnot on this mapstarted 2022, after this paper: background citation

Fertility and the Microbiome: an Observational Study and Randomized Placebo Controlled Double-blind Pilot Trial

TypeobservationalSponsorMedical University of GrazRan2022 to 2026Enrolled300ConditionsSubfertility, AsthenozoospermiaArmsProbiotics (Omnibiotic (R))
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Increased vaginalmSystems · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Rivka KoedooderDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands. r.koedooder@erasmusmc.nl.ORCID http://orcid.org/0000-0002-0233-6312
Martin SingerLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Centre, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.
Sam SchoenmakersDivision Obstetrics, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
Paul Hendrik Maria SavelkoulLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Centre, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.
Servaas Antonie MorréLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Centre, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.
Jonathan Dennis de JongeARTPred B.V., Kruisweg 647, 2131 NC, Hoofddorp, The Netherlands.
Linda PoortIS-Diagnostics Ltd, spin-off at Department of Medical Microbiology and Infection Control, VU University Medical Centre, de Boelelaan 1108, 1081 HZ, Amsterdam, The Netherlands.
Willem-Jan Simon Stephanus CuypersDutch Division, MVZ VivaNeo Kinderwunschzentrum Düsseldorf GmbH, Völklinger Straße 4, 40219, Düsseldorf, Germany.
Andries Edward BuddingLaboratory of Immunogenetics, Department of Medical Microbiology and Infection Control, VU University Medical Centre, De Boelelaan 1108, 1081 HZ, Amsterdam, the Netherlands.
Joop Stephanus Elisabeth LavenDivision of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus University Medical Centre, Wytemaweg 80, 3015 CN, Rotterdam, The Netherlands.
ReceptIVFity study group
Amsterdam UMC Location Vrije Universiteit Amsterdam · NLErasmus MC · NLMaastricht University · NLMaastricht University Medical Centre · NLWestern Digital (Netherlands) · NL

Funding

Eurostars (Valbiome) 8884
6 · The paper itself

Abstract

backgroundDuring the last decade, research has shown that besides the known predictive factors, such as duration of subfertility, a women's age, the body mass index, also the microbiome might affect fertility. Micro-organisms together with their genetic information and the milieu in which they interact are called the microbiome. Studies have shown that the presence of certain microbiota during assisted reproductive technology (ART) has a positive impact on the outcome. However, the potential role of using the microbiome as a predictor for outcome of ART has not yet been investigated.

methodsIn a prospective study, 300 women of reproductive age and with an indication for in-vitro Fertilization (IVF) with or without Intra Cytoplasmic Sperm Injection (ICSI) treatment will be included. Prior to the IVF or IVF-ICSI treatment, these women provided a midstream urine sample and a vaginal swab. The composition of the urinary and vaginal microbiome will be analysed with both Next Generation Sequencing and the IS-pro technique. The endpoints of the study are pregnancy achieved after fresh embryo transfer (ET) and within the subsequent year after inclusion. External validation of the findings will take place in an additional cohort of 50 women with an IVF or IVF-ICSI indication. DISCUSSION: In the proposed study, the predictive accuracy of the composition of the urinary and vaginal microbiome for IVF or IVF-ICSI outcome will be only validated for fresh ET. Follow-up has to show whether the predictive accuracy will be similar during the consecutive frozen ET's as part of the IVF or IVF-ICSI treatment or for subsequent stimulated or natural cycles. In addition, external validation will take place in another cohort and hospital. Predictive knowledge of the microbiome profile may enable couples to make a more substantiated decision on whether to continue treatment or not. Hence, the unnecessary physical and emotional burden of a failed IVF or IVF-ICSI treatment can be avoided.

trial registrationISRCTN ISRCTN83157250 . Registered 17 August 2018. Retrospectively registered.

Indexed as

Fertilization in VitroAdultAlgorithmsBacteriaCohort StudiesFemaleHumansInfertility, FemaleMicrobiotaPregnancyPregnancy RatePrognosisReproducibility of ResultsResearch DesignSperm Injections, IntracytoplasmicUrineImplantationMicrobiotaPredictionUrinaryVaginal

Identifiers

PMID30526664
PMCPMC6286554
OpenAlexW2904024828

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.